Methods for diagnosis and treatment of COVID-19 acuity in a subject include the identification of a subject as having Nan increased expression level and/or activity of thymidine phosphorylase in a biological sample obtained from the subject. An effective amount of a therapeutic agent that reduces the expression level or activity of thymidine phosphorylase can the be administered to the subject.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

A system for the electrochemical detection of analyte levels includes a test strip including an electrode and a counter electrode, the electrode and counter electrode located proximate to a sample reception area. The system further includes a coating on one of the electrode and counter electrode, the coating including a reagent coating for an analyte. The reagent coating includes a creatinine iminohydrolase, deamido NAD.sup.+, ATP, and NAD Synthetase/Mg.sup.2+.

The invention is directed to electrochemical detection systems, components thereof, materials and methods for making the systems and components thereof, and methods for detecting analytes with the systems. The systems include electrochemical cells containing hydrogels. The hydrogels include polymers with amine-containing pendant groups. The polymers can be cross-linked via the amine-containing pendant groups. The polymers can also or alternatively include enzymes and/or electron shuttles tethered thereto via amine-containing pendant groups. Monomers for making the polymers are provided. The systems can be used to detect analytes such as glucose.

Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

Provided is a compound having the structure:

(SIG)-(SI-MOD).sub.m

where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.

Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

An ascorbic acid responsive electrode comprising an electrode, and a detection layer comprising a non-catalytic electron acceptor that receives an electron from ascorbic acid, an amino acid, and a saccharide and/or a soluble protein; wherein in the detection layer the electron acceptor is reduced by the ascorbic acid, and the reduced electron acceptor is oxidized at the electrode.

Methods of diagnosing infections are disclosed. In one embodiment, the method comprises measuring the amount of each of the polypeptides TRAIL, CRP, IP10 and at least one additional polypeptide selected from the group consisting of IL-6 and PCT.

There is provided protein biomarkers and methods for their use in diagnosing and treating Inflammatory Bowel Disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) as well as methods for assessing the severity of the diseases.